While the molecular mechanisms linking hepatic steatosis and myeloid Lpcat3 deficiency remain to be elucidated, our hypothesis is that changes in AA metabolism-restricted liver myeloid cells may secondarily impact AA homeostasis in the whole liver leading to metabolic disorders and TG accumulation. This evidence concerns the gene LPCAT3 and fatty liver disease.